Many ALK-TKIs have been recommended by the NSCLC clinical guidelines, such as the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN) (11), Guidelines of the Chinese Society of Clinical Oncology (CSCO) for NSCLC (6), and the European Society for Medical Oncology (ESMO) (12). Here, ALK is linked to non-small cell lung carcinoma.